So we have fewer deaths in our Phase III s/c trial

So we have fewer deaths in our Phase III s/c trials, at Interim analysis, than many other trials? Was deaths reported at 45 accurate, and maybe that has increased when looking beyond the 28 days at those 195 patients?

Some folks have speculated data math and p value based on 45 deaths, and further then speculated, based on their math, that there is a reasonable or good chance we could achieve Statistical Significance.